“…Despite the vaccine only having impact on reducing hospitalizations due to pneumonia caused by Streptococcus pneumoniae serotypes or by serotypes corresponding to them, 14 and present in its composition, Domingues et al reported that in 2014 in ten Brazilian states, vaccination with three doses of PCV10 was associated with an 84% reduction (95%CI: 66;92) in invasive pneumococcal disease (IPD), through serotypes present in the vaccine (serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F), as well as a 78% reduction (95%CI: 41;92) in the serotypes corresponding to the vaccine (6A and 19A), when immunological cross-reactivity was reported. 15,23 In turn, research conducted in Salvador in 2002, with strains isolated from the blood of children and adolescents hospitalized with pneumonia and fever without localized symptoms, identified predominance of serotypes 14, 5, 6A, 6B, 19F, 9V, 18C and 23F in that population.…”